Below are the most recent publications written about "Dasatinib" by people in Profiles.
-
Friedman Ohana R, Levin S, Hurst R, Rosenblatt MM, Zimmerman K, Machleidt T, Wood KV, Kirkland TA. Streamlined Target Deconvolution Approach Utilizing a Single Photoreactive Chloroalkane Capture Tag. ACS Chem Biol. 2021 02 19; 16(2):404-413.
-
Martyanov V, Kim GJ, Hayes W, Du S, Ganguly BJ, Sy O, Lee SK, Bogatkevich GS, Schieven GL, Schiopu E, Marangoni RG, Goldin J, Whitfield ML, Varga J. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One. 2017; 12(11):e0187580.
-
Barkoulas T, Hall PD. Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract. 2018 Mar; 24(2):121-128.
-
Balasubramanian S, Pleasant DL, Kasiganesan H, Quinones L, Zhang Y, Sundararaj KP, Roche S, O'Connor R, Bradshaw AD, Kuppuswamy D. Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. PLoS One. 2015; 10(10):e0140273.
-
Moore TL, Grimes SW, Lewis RL, Alexis F. Multilayered polymer-coated carbon nanotubes to deliver dasatinib. Mol Pharm. 2014 Jan 06; 11(1):276-82.
-
Separovic D, Breen P, Boppana NB, Van Buren E, Joseph N, Kraveka JM, Rahmaniyan M, Li L, Gudz TI, Bielawska A, Bai A, Bielawski J, Pierce JS, Korbelik M. Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation. Int J Oncol. 2013 Dec; 43(6):2064-72.
-
Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
-
Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P. Imatinib resistance and microcytic erythrocytosis in a KitV558?;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A. 2012 Aug 21; 109(34):E2276-83.
-
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
-
Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009 Nov; 338(5):414-7.